SPL 2.33% $1.47 starpharma holdings limited

2015 a Watershed Year for Starpharma, Says Bell Potter

  1. 166 Posts.
    lightbulb Created with Sketch. 3
    DJ 2015 a Watershed Year for Starpharma, Says Bell Potter -- Market Talk
    [5:48 ET] Starpharma's (SPL.AU) recent A$21.5 million capital raising prompts Bell
    Potter to cut its price target by 10% to A$0.99/share, but the broker remains upbeat
    about the stock's prospects. Starpharma's cash balance stands at around A$39.3
    million, which would allow it comfortably to progress its pipeline of advanced drugs, the
    broker says. Interest is building in Starpharma's dendrimer-docetaxel drug in
    development, following positive preliminary data from trials on animals and a phase-one
    trial in humans. Bell Potter, which retains a buy call, says the company is better
    equipped to engage in meaningful licensing discussions with both existing and potential
    partners on its various drug-delivery program. Separately, Bell Potter thinks
    Starpharma's VivaGel Coated Condom will start generating revenue from the second
    half of 2015, rising to US$20 million in FY21 as the product is launched in new markets
    and marketing encourages more people to try it. SPL last traded at A$0.475.
watchlist Created with Sketch. Add SPL (ASX) to my watchlist
(20min delay)
Mkt cap $543.8M
Open High Low Value Volume
$1.50 $1.51 $1.46 $238.0K 161.2K

Buyers (Bids)

No. Vol. Price($)
2 12476 $1.46

Sellers (Offers)

Price($) Vol. No.
$1.48 2303 1
Last update - 16.10pm 22/10/2018 (20 minute delay) ?
-0.04 ( 1.09 %)
Open High   Low Volume
$1.50 $1.51   $1.46 51033
Last updated 15.59pm 22/10/2018 (live) ?
SPL (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.